Left Menu
Development News Edition

Lilly says antibody reduces need for hospitalization for moderate COVID-19 patients

Eli Lilly & Co said on Wednesday that its experimental antibody reduced the need for hospitalization and emergency room visits for patients with moderate COVID-19, according to an interim analysis of a mid-stage clinical trial. The study tested three different doses of LY-CoV555, a manufactured antibody designed to recognize and lock onto the novel coronavirus, preventing the infection from spreading.

Reuters | Updated: 16-09-2020 16:27 IST | Created: 16-09-2020 16:16 IST
Lilly says antibody reduces need for hospitalization for moderate COVID-19 patients
Representational Image Image Credit: ANI

Eli Lilly & Co said on Wednesday that its experimental antibody reduced the need for hospitalization and emergency room visits for patients with moderate COVID-19, according to an interim analysis of a mid-stage clinical trial.

The study tested three different doses of LY-CoV555, a manufactured antibody designed to recognize and lock onto the novel coronavirus, preventing the infection from spreading. Of the total 302 patients treated with three different doses of LY-CoV555, five of them, or 1.7%, had to be admitted to a hospital or visit a hospital emergency room. That compares with a rate of 6%, or 9 out of 150, for trial patients given a placebo, the company said.

Only the middle dose, 2,800 milligrams, achieved the trial's main goal of reducing the amount of virus detected in patients compared to a placebo 11 days after treatment, it added. No drug-related serious adverse events were reported and there have been no trial deaths.

Lilly said it expects to publish the results of the interim analysis in a peer-reviewed journal and discuss appropriate next steps with global regulators. The company said most hospitalizations occurred in patients with underlying risk factors such as being elderly or obese, suggesting a more pronounced treatment effect for people in these higher-risk groups.

"The results reinforce our conviction that neutralizing antibodies can help in the fight against COVID-19," Daniel Skovronsky, Lilly's chief scientific officer, said in a statement. The company said the trial was ongoing and has now enrolled 800 patients with mild-to-moderate COVID-19. The trial is also studying LY-CoV555 in combination with a second Lilly antibody, LY-CoV016, which binds a different area of the coronavirus' spike protein.

The antibodies, which are given by intravenous infusion, are also being tested for preventing COVID-19 in residents and staff at long-term care facilities and for treating patients already hospitalized due to COVID-19.


TRENDING

OPINION / BLOG / INTERVIEW

Post-COVID-19 Nigeria needs a robust Health Management Information System to handle high disease burden

Nigeria is among a few countries that conceptualised a health management information system HMIS in the early 90s but implementation has been a challenge till date. Besides COVID-19, the country has a huge burden of communicable and non-com...

Morocco COVID-19 response: A fragile health system and the deteriorating situation

Learning from its European neighbors, Morocco imposed drastic measures from the initial stages of the COVID-19 outbreak to try to contain its spread. The strategy worked for a few months but the cases have surged after mid-June. In this sit...

COVID-19: Argentina’s health system inefficiencies exaggerate flaws of health information system

You can recover from a drop in the GDP, but you cant recover from death, was the straightforward mindset of Argentinas President Alberto Fernndez and defined the countrys response to COVID-19. The South American nation imposed a strict...

Rwanda’s COVID-19 response commendable but health information system needs improvement

Rwanda is consistently working to improve its health information system from many years. However, it is primarily dependent on the collection and reporting of health data on a monthly basis. Besides, evaluation studies on Rwandas HIS publis...

Videos

Latest News

Thai protesters hold ambitious rally for democratic reforms

Protesters gathered Saturday in Bangkok for the most ambitious rally so far in a pro-democracy campaign that has shaken up the government and Thailands conservative establishment. Organisers predicted that as many as 50,000 will march over ...

Farm Bills: SAD's 'real face' exposed; Harsimrat's resignation 'unsuccessful drama', says Dhindsa

Dissident Shiromani Akali Dal SAD leader Sukhdev Singh Dhindsa on Saturday said the party stood exposed for its double-speak on the farm bills and asked why Harsimrat Kaur Badal did not resign as minister when the Union Cabinet cleared the ...

US News Roundup: Trailblazing U.S. Supreme Court Justice Ginsburg dies; Amid mourning for Ginsburg, fierce battle over U.S. Supreme Court looms and more

Following is a summary of current US domestic news briefs.Trailblazing U.S. Supreme Court Justice Ginsburg dies succession battle loomsJustice Ruth Bader Ginsburg, a stalwart liberal on the U.S. Supreme Court since 1993, died on Friday at a...

Odd News Roundup: Ig Nobel science award: An alligator on helium sounds like ...?

Following is a summary of current odd news briefs.Ig Nobel science award An alligator on helium sounds like ...If humans sound like Minnie Mouse after inhaling helium, would an alligator squeak on the gas used to float balloons This profoun...

Give Feedback